Unique ID issued by UMIN | UMIN000041098 |
---|---|
Receipt number | R000046878 |
Scientific Title | Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G) |
Date of disclosure of the study information | 2020/07/15 |
Last modified on | 2023/01/10 09:32:34 |
Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)
A Multi-institutional retrospective study for Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer (WJOG13219G)
Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)
A Multi-institutional retrospective study for Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer (WJOG13219G)
Japan |
BRAF V600E-mutant Metastatic Colorectal Cancer
Gastroenterology | Hematology and clinical oncology |
Malignancy
NO
To evaluate the efficacy and safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer retrospectively
Others
Evaluation of clinical data
Overall survival
Observational
Not applicable |
Not applicable |
Male and Female
1) histologically confirmed colorectal cancer (CRC)
2) diagnosed unresectable or recurrent CRC and initiated first-line chemotherapy including two or all of fluoropyrimidine, irinotecan, and oxaliplatin between April 2014 and December 2019
3) detected BRAF V600E mutation in tumor tissue confirmed by real-time polymerase chain reaction (PCR), or next generation sequencing (NGS)
1) patients with another concomitant cancer at the time of diagnosis
250
1st name | Kenro |
Middle name | |
Last name | Hirata |
Keio University School of Medicine
Gastroenterology and Hepatology
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-1211
kenro916@gmail.com
1st name | Shinichiro |
Middle name | |
Last name | Nakamura |
West Japan Oncology Group
WJOG datacenter
556-0016
Namba Plaza Bldg. 304-1-5-7, Motomachi Naniwa-ku, Osaka, JAPAN
06-6633-7400
datacenter@wjog.jp
West Japan Oncology Group
Self-funding
Self funding
The Keio University Hospital Institutional Ethics Committee
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-1211
kshimozaki@keio.jp
NO
2020 | Year | 07 | Month | 15 | Day |
Unpublished
Completed
2020 | Year | 07 | Month | 13 | Day |
2020 | Year | 09 | Month | 01 | Day |
2020 | Year | 12 | Month | 24 | Day |
2021 | Year | 03 | Month | 31 | Day |
We will review medical records and collect data on baseline characteristics, clinical outcomes, and treatment-related adverse events of grade greater than 3 according to the Common Terminology Criteria for Adverse Events version 4.0.
2020 | Year | 07 | Month | 14 | Day |
2023 | Year | 01 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046878
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |